Background
Pharmaceutical companies have been actively taking early scientific advice from health technology assessment (HTA) agencies during development, with the aim to understand the HTA evidentiary requirements. The evolving advice landscape, including multi-stakeholder and international collaborations, highlights the importance of proactive engagement. This opinion survey assessed international pharmaceutical companies’ current experiences in seeking early HTA advice, explored strategies for forward looking actions and considerations.
Method
An opinion survey was designed and conducted in November 2023, as a cross-sectional questionnaire consisting of multiple-choice questions. The questionnaire provided a qualitative assessment of companies’ current strategies and experiences in taking early HTA advice as well as future considerations. Eligible survey participants were the senior management of Global HTA/Market Access Departments at top international pharmaceutical companies. Twelve out of 20 companies responded.
Conclusion
This survey assessed companies’ practices in seeking early HTA advice, with most engaging national agencies such as NICE and G-BA. The lack of current JSC participation, despite companies’ prioritization, highlights the agencies’ need to enhance capacity and resources. Survey results underscored the importance of companies’ adaptive strategies in the evolving environment, which can be supported by active measures of advice success.
This poster was presented at the 2024 HTAi Annual Meeting, 15-19th June 2024, Seville, Spain.
